Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

From symptomatic relief to restorative medicine: a comprehensive review of diabetic erectile dysfunction

Wang H., Li C., Zhang T., Li S.

Narrative Review on Systemic / IV, published in Transl Androl Urol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Transl Androl Urol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41971122
PMCID
PMC13062855
DOI
10.21037/tau-2025-1-945

Abstract (original English)

Diabetic erectile dysfunction (DMED) represents one of the most prevalent and debilitating complications in men with diabetes, characterized by a complex multifactorial pathogenesis and often suboptimal response to conventional therapies. This review comprehensively summarizes the current understanding of DMED mechanisms and evaluates the evolving therapeutic landscape. We highlight oxidative stress as a pivotal central hub triggered by hyperglycemia, which orchestrates a cascade of detrimental events. Beyond classical endothelial dysfunction and RhoA/ROCK pathway activation, we discuss emerging pathogenic targets, including the activation of the NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome leading to pyroptosis, ferroptosis-induced smooth muscle loss, and epigenetic dysregulation (e.g., upregulated miR-155). Furthermore, the "gut-penis axis" is explored as a novel link between microbiota dysbiosis and systemic inflammation affecting erectile function. Critically, this review assesses the paradigm shift from symptomatic management to restorative therapies. While phosphodiesterase type 5 inhibitors (PDE5i) remain the first-line treatment, they exhibit a non-response rate of approximately 40-50% in diabetic men due to severe neuropathy and endothelial damage. Consequently, emerging regenerative modalities are gaining prominence. We evaluate the efficac

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research